journal
MENU ▼
Read by QxMD icon Read
search

Future Oncology

journal
https://www.readbyqxmd.com/read/28523933/the-pazoreal-noninterventional-study-to-assess-effectiveness-and-safety-of-pazopanib-and-everolimus-in-the-changing-metastatic-renal-cell-carcinoma-treatment-landscape
#1
Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß, Manfred Welslau
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab...
May 19, 2017: Future Oncology
https://www.readbyqxmd.com/read/28513194/long-noncoding-rnas-emerging-regulators-of-tumor-angiogenesis
#2
Su-Rui Sheng, Jia-Shun Wu, Ya-Ling Tang, Xin-Hua Liang
Long noncoding RNAs (lncRNAs) participate in multiple biological processes especially human diseases, of which, tumor seems to be one of the most significant. Angiogenesis has been deemed to have a pivotal role in a series of tumor biological behaviors in tumorigenesis, progression and prognosis. Emerging evidences suggested that lncRNAs are involved in tumor angiogenesis and lncRNAs have already been verified to be potential biomarkers and promising therapeutic targets. This review summarized emerging angiogenesis-related lncRNAs, discussed their mechanisms interacting with cytokines, cancer stem cells, miRNAs and tumor hypoxia microenvironment, and demonstrated if lncRNAs could be new candidate targets of antiangiogenesis therapy...
May 17, 2017: Future Oncology
https://www.readbyqxmd.com/read/28498036/combination-radiotherapy-and-cantharidin-inhibits-lung-cancer-growth-through-altering-tumor-infiltrating-lymphocytes
#3
Yan Zhang, Shu-Li Yang, Hong-Rui Zhang, Ling Gao, Xin Gao, Pei-Jie Liu, Zhen-Ying Yi, Ning Li, Zhi-Qiao Xu
This study aimed to detect the effect of combination radiotherapy and cantharidin on lung cancer growth. We found that combination therapy with radiotherapy and cantharidin was more effective in inhibiting the tumor growth than radiotherapy or cantharidin alone. It decreased the percentage of CD4(+) Tregs and enhanced the percentage of CD8(+) T cells, CD4(+) Teff cells when comparing to that of single treatment. Combination therapy promoted a great increase in double producing CD8(+) T cells and CD4(+) Teff cells in tumor infiltrating lymphocytes...
May 12, 2017: Future Oncology
https://www.readbyqxmd.com/read/28492350/the-underestimated-role-of-somatostatin-analogs-in-the-netter-1-trial
#4
Sara Pusceddu, Roberto Buzzoni, Filippo de Braud
No abstract text is available yet for this article.
May 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28492339/venetoclax-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia
#5
Jennifer Crombie, Matthew S Davids
Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis in chronic lymphocytic leukemia (CLL) cells. In early-phase clinical trials in CLL, venetoclax treatment led to tumor lysis syndrome in some patients with a large tumor burden, but this risk was subsequently mitigated by a revised study design that included lower initial dosing with intrapatient dose ramp-up and close tumor lysis syndrome monitoring and prophylaxis...
May 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28492089/does-physical-activity-improve-survival-and-mortality-among-patients-with-different-types-of-cancer
#6
Shinichiro Morishita, Atsuhiro Tsubaki, Jack B Fu
No abstract text is available yet for this article.
May 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28492088/donor-selection-for-ex-vivo-expanded-natural-killer-cells-as-adoptive-cancer-immunotherapy
#7
Wei Wang, Amy K Erbe, Kenneth B DeSantes, Paul M Sondel
No abstract text is available yet for this article.
May 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28492086/novel-translational-therapeutic-strategy-by-sequencing-primary-liver-cancer-genomes
#8
Georgios K Glantzounis, Ioannis D Kyrochristos, Demosthenes E Ziogas, Efstathios G Lykoudis, Dimitrios H Roukos
No abstract text is available yet for this article.
May 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28485672/axitinib-in-metastatic-renal-cell-carcinoma-patient-characteristics-and-treatment-patterns-in-us-community-oncology-centers
#9
Thomas E Hutson, Xiaolong Jiao, Thomas Wilson, Laura Cisar, Elizabeth A MacLean
AIM: To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma. PATIENTS & METHODS: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database. RESULTS: Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55...
May 9, 2017: Future Oncology
https://www.readbyqxmd.com/read/28460537/rising-options-in-advanced-soft-tissue-sarcomas-present-and-future-treatment-sequences
#10
José Casanova
No abstract text is available yet for this article.
May 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28460536/review-of-past-and-present-clinical-cases-with-a-view-to-future-treatment-options
#11
Javier Martín-Broto, Peter Reichardt, Silvia Stacchiotti, Jean-Yves Blay
In the 10 years that have elapsed since trabectedin was first granted approval in Europe for treatment of advanced soft tissue sarcoma (STS), other cytotoxic agents and targeted therapies have been approved and numerous randomized controlled trials have been completed or are underway. As an academic exercise and positive proof of the advances in STS management that have occurred during the past decade, it is interesting to compare current and future treatment approaches. In this review, present and future treatment approaches are examined by case study for three STS subtypes: uterine leiomyosarcoma, abdominal dedifferentiated liposarcoma and malignant solitary fibrous tumor...
May 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28460535/intensity-of-recent-years-in-the-investigation-of-soft-tissue-sarcoma
#12
Jean-Yves Blay
The European Medicines Agency's approval in 2007 of trabectedin for treatment of advanced soft tissue sarcoma (STS) - the first new agent approved in this indication for more than 30 years - coincided with the start of an exciting era in sarcoma research. Over the past 10 years, several other cytotoxic agents and targeted therapies have been approved for use in advanced STS and research efforts continue to intensify. In parallel, the virtual explosion of new evidence has presented its own set of challenges in terms of interpreting the data and understanding how it may apply to individual patients...
May 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28453299/proposed-biosimilar-pegfilgrastim-la-ep2006-compared-with-reference-pegfilgrastim-in-asian-patients-with-breast-cancer-an-exploratory-comparison-from-two-phase-iii-trials
#13
Nadia Harbeck, Pere Gascon, Clyde M Jones, Allen Nixon, Andriy Krendyukov, Roumen Nakov, Yuhan Li, Kimberly Blackwell
AIM: This is a pooled subgroup analysis of Asian patients enrolled in two Phase III confirmatory studies comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in women receiving chemotherapy for breast cancer. PATIENTS & METHODS: Women were randomized to LA-EP2006 (n = 90) or reference (n = 84) pegfilgrastim (Neulasta(®), Amgen, Inc., CA, USA) for ≤6 cycles of TAC chemotherapy. Primary end point was duration of severe neutropenia during Cycle 1 (number of consecutive days with absolute neutrophil count <0...
April 28, 2017: Future Oncology
https://www.readbyqxmd.com/read/28443700/role-of-everolimus-in-the-treatment-of-metastatic-her2-negative-hr-positive-breast-cancer
#14
Pronzato Paolo
Metastatic breast cancer (mBC) is a leading cause of mortality for women around the world. The response to hormonotherapy of the patients with HER2-negative/HR-positive mBC is usually limited, and many strategies are in place to contrast the hormonotherapy resistance. Since efficacy and effectiveness of everolimus have been established by many trials, this review is aimed to give a structured synthesis to define the everolimus clinical role among the treatment options for mBC. Key aspects of everolimus dosing and safety profile, drawn up by relevant findings, are included, as well as the role of biomarkers to identify subgroups of mBC patients who may best benefit from everolimus treatment...
April 26, 2017: Future Oncology
https://www.readbyqxmd.com/read/28440086/debiri-plus-capecitabine-a-treatment-option-for-refractory-liver-dominant-metastases-from-colorectal-cancer
#15
Vincenzo Di Noia, Michele Basso, Valentina Marsico, Eleonora Cerchiaro, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Giovanni Schinzari, Roberto Iezzi, Alessandra Cassano, Carlo Barone
AIM: This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS: Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI at 2-week interval or two DEBIRI every 4 weeks for bilobar or single-lobe metastases, respectively. Capecitabine was given at 1000 mg/m(2) twice daily on days 1-14 every 3 weeks...
April 25, 2017: Future Oncology
https://www.readbyqxmd.com/read/28436242/current-status-of-ramucirumab-in-gastroesophageal-adenocarcinoma
#16
Elena Elimova, Quan Lin, Shumei Song, Jaffer A Ajani
Outcomes of patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEAC) remain poor despite recent advances. The standard of care in the management of this disease had not changed much over the past decade. In the first line, a platinum containing doublet/triplet is used, while in <20% of patients with human epithelial growth factor receptor type 2 overexpressing GEACs, trasuzumab can provide a modest advantage. Until recently, no standard second-line regimens existed; however, the results of the REGARD and RAINBOW trials led to the approval of ramucirumab in the second-line setting...
April 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28429617/esas-and-fact-b-in-eribulin-treated-metastatic-breast-cancer-patients-a-multicenter-prospective-and-observational-study
#17
Luca Moscetti, Lucia Mentuccia, Patrizia Vici, Silvia Quadrini, Isabella Sperduti, Laura Pizzuti, Maria Agnese Fabbri, Angela Vaccaro, Marcello Maugeri Saccà, Maddalena Barba, Domenico Sergi, Germano Zampa, Teresa Gamucci
AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations. PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires...
April 21, 2017: Future Oncology
https://www.readbyqxmd.com/read/28427281/the-servier-oncology-pipeline-in-2017
#18
Patrick Therasse, Beatrice Perron, Sarah A Novack, Jean-Pierre Abastado
Cancer is a complex, multifactorial disease that for years has been the focus of intensive research efforts to explore both the molecular and biological mechanisms involved and the development of novel agents to target these pathways. Servier is an independent French pharmaceutical company with a focus on oncology. Currently, Servier's commercial portfolio includes agents used to treat non-Hodgkin's lymphoma and metastatic colorectal cancer; Servier's oncology pipeline involves agents for the treatment of both solid and hematological tumors...
April 21, 2017: Future Oncology
https://www.readbyqxmd.com/read/28395525/end-points-and-statistical-considerations-in-immuno-oncology-trials-impact-on-multiple-myeloma
#19
Antje Hoering, Brian Durie, Hongwei Wang, John Crowley
Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate study designs, end points and statistical methods are essential for evaluating immuno-oncology therapies to assess treatment outcomes, and may better accommodate immuno-oncology clinical trial data. In addition to conventional end points including median progression-free survival (PFS) and overall survival (OS), end points such as hazard ratios for PFS and OS over time, PFS and OS landmark analyses beyond the median, and immune-response end points might provide better indications of the efficacy of immuno-oncology therapies...
April 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28381104/postmastectomy-radiation-therapy-for-breast-cancer-patients-with-one-to-three-positive-lymph-nodes-a-propensity-score-matching-analysis
#20
Jiamao Lin, Cheng Li, Chenyue Zhang, Fang Shi, Haiyong Wang
AIM: Conducting postmastectomy radiation therapy (PMRT) for breast cancer patients with one to three positive lymph nodes is still controversial. METHODS: Propensity score matching analysis was applied to balance the clinical baseline characteristics of patients. Cox proportional hazard analysis was used to analyze the survival prognosis factors and perform subgroup analysis. RESULTS: There was no statistical difference in overall survival and cancer-specific survival rates (all, p > 0...
April 6, 2017: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"